Xtl Biopharmaceuticals (XTLB) Non-cash Items (2009 - 2016)
Xtl Biopharmaceuticals (XTLB) posted quarterly Non-cash Items of -$31000.0 for Q2 2016, up 64.37% year-on-year from -$18860.1 in Q3 2015, and up 94.82% on a QoQ basis from -$599000.0 in Q4 2015.
Xtl Biopharmaceuticals (XTLB) Non-cash Items (2009 - 2016) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Non-cash Items for 8 consecutive years, with -$31000.0 the latest figure, recorded in Q2 2016.
- Quarterly Non-cash Items rose 64.37% year-over-year to -$31000.0 in Q2 2016, while the trailing twelve-month figure through Jun 2016 was -$712000.0 (down 306.98% YoY) and the FY2025 annual result came in at -$2000.0, down 101.06% from the prior year.
- Non-cash Items rose to -$31000.0 in Q2 2016 per XTLB's latest filing, from -$599000.0 in the prior quarter.
- Over the last five years, Non-cash Items for XTLB reached as high as $1.3 million in Q4 2013 and fell as low as -$1.2 million in Q3 2013.
- A 5-year average of $70812.5 and a median of $99500.0 in 2012 frame the typical range for Non-cash Items.
- Annual changes were most pronounced in 2013 — Non-cash Items jumped 822.86% — and 2015, when it tumbled 494.08%.
- Year by year, Non-cash Items stood at $140000.0 in 2012, then soared by 822.86% to $1.3 million in 2013, then sank by 88.24% to $152000.0 in 2014, then slumped by 494.08% to -$599000.0 in 2015, then jumped by 94.82% to -$31000.0 in 2016.
- According to Business Quant data, Non-cash Items over the past three periods registered -$31000.0, -$599000.0, and $5000.0 for Q2 2016, Q4 2015, and Q3 2015 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn |
| 10 | Xtl Biopharmaceuticals | 2.51 Bn | 2.51 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | -31,000.00 |
| Jun 30, 2016 | -31,000.00 |
| Dec 31, 2015 | -599,000.00 |
| Dec 31, 2015 | -599,000.00 |
| Sep 30, 2015 | 5,000.00 |
| Sep 30, 2015 | 5,000.00 |
| Jun 30, 2015 | -87,000.00 |
| Jun 30, 2015 | -87,000.00 |
| Dec 31, 2014 | 152,000.00 |
| Dec 31, 2014 | 152,000.00 |
| Sep 30, 2014 | 113,000.00 |
| Sep 30, 2014 | 113,000.00 |
| Jun 30, 2014 | 166,000.00 |
| Jun 30, 2014 | 166,000.00 |
| Mar 31, 2014 | -36,000.00 |
| Mar 31, 2014 | -36,000.00 |
| Dec 31, 2013 | 1.29 Mn |
| Dec 31, 2013 | 1.29 Mn |
| Sep 30, 2013 | -1.20 Mn |
| Sep 30, 2013 | -1.20 Mn |